PATENT CLAIM ANALYSIS

Application Number: 15749854
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "062000"]

Abstract:
Disclosed is a TLR4 agonist alone or in combination with an anti-cancer agent and pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said composition or combination, including uses in cancer.

Claim (Index 15):
The method as claimed in  claim 13 , wherein the anti-cancer agent and the TLR4 agonist, CRX-601, are administered sequentially, in any order.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 88.0
- Lexical Diversity: 1.27586
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15006560', '14256521', '14333758', '14836115', '15246662']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7355746515147773
- 35 USC 102 Novelty (BERT): 0.5039841466903819
- Combined Prediction Score: 0.7124156010323377
- Mean Citation Score: 213.510648
- Max Citation Score: 235.97655
- Similarity Product: 159.173381707263

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test